Suggested remit: To appraise the clinical and cost effectiveness of imlifidase within its marketing authorisation for desensitisation treatment before kidney transplantation in highly sensitised people with chronic kidney disease.
Status Proposed
Process STA 2018
ID number 1672

Provisional Schedule

Committee meeting: 1 11 March 2021

Project Team

Project lead Gavin Kenny

Email enquiries


Companies sponsors Hansa Biopharma (imlifidase)
Others Department of Health and Social Care
  NHS England
  NHS Rotherham CCG
  NHS Surrey Downs CCG
  Welsh Government
Patient carer groups Kidney Care UK
  Kidney Research UK
  Muslim Council of Britain
  National Kidney Federation
  Network of Sikh Organisations
  Polycystic Kidney Disease Charity
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of Anaesthetists
  Association of Renal Technologists
  Association of Surgeons of Great Britain and Ireland
  British Association of Urological Nurses
  British Association of Urological Surgeons
  British Geriatrics Society
  British Renal Society
  British Transplantation Society
  NHS Blood and Transplant
  Renal Association
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for DGH Nephrologists
  UK Clinical Pharmacy Association
  UK Renal Pharmacy Group


Associated public health groups Public Health England
  Public Health Wales
General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Association of Renal Industries
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Welsh Kidney Patients Association
Relevant research groups Cochrane Kidney and Transplant Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
11 May 2020 Invitation to participate
06 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
17 January 2020 (10:00) Scoping workshop (Manchester)
14 November 2019 - 12 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance